ImmVirX Poster Presentations on Preclinical and Clinical Programs at AACR Annual Meeting, Chicago
Melbourne, Australia 27 March 2025 – ImmVirX Pty Limited, a life sciences company focused on developing next-generation, receptor targeted oncolytic RNA immunotherapies to transform outcomes for patients with some of the most prevalent and challenging cancer types, will present two posters at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April […]
ImmVirX receives $5.1 million R&D Tax Incentive
Melbourne, Australia 15 January 2025 – ImmVirX Pty Limited, a life sciences company focused on developing next-generation, receptor targeted oncolytic RNA immunotherapies to transform outcomes for patients with some of the most prevalent and challenging cancer types, has received a $5,079,136 Research and Development (R&D) tax refund as part of the Australian Federal Government’s R&D […]
First patients dosed in Phase 1b combination study in colorectal, gastric and ovarian cancer
Phase 1b trial will evaluate IVX037 and Innovent Bio’s anti-PD-1 inhibitor TYVYT® (sintilimab) in patients with late stage colorectal, gastric and ovarian cancer Trial open at 4 sites with further sites to open through Q4. Melbourne, Australia 28 October 2024 – ImmVirX Pty Limited, a clinical stage oncology company focused on developing next-generation, receptor targeted […]
ImmVirX reports on operations for FY24
Melbourne, Australia 1 October 2024 – ImmVirX Pty Limited, a life sciences company dedicated to pioneering the next generation of receptor-targeted immunotherapies for patients confronted with common yet formidable cancers, is pleased to provide a summary of its operations for the financial year ended 30 June 2024. The principal activity during the financial year was the […]
ImmVirX presents update on Phase 1a/b Clinical Study at Medical Oncology Group of Australia Annual Meeting
Strong recruitment with 14 patients to date – four sites open + more shortly. Well tolerated, no dose-limiting toxicities. Signs of anti-cancer monotherapy activity in 2 of first 10 late-stage colorectal cancer patients evaluable for response. Late-stage colorectal cancer patient with complete response in injected lesion and no new metastatic disease over one year since […]
ImmVirX appoints Dr. Oksana Zdanska as Medical Director
Melbourne, Australia, 16 April 2024 – ImmVirX Pty Limited, a life sciences company dedicated to pioneering the next generationof receptor-targeted immunotherapies for patients confronted with common yet formidable cancers, is pleased to announce the appointment of Dr Oksana Zdanska as Medical Director, commencing today. Dr. Zdanska is a highly regarded clinical leader with extensive experience […]
ImmVirX presents on its Phase 1a Clinical Study at Society for Immunotherapy of Cancer (SITC) Annual Meeting
Strong recruitment – commenced April 2023, 8 patients to date. Strong clinician interest across multiple sites. Intralesional administration well tolerated, no dose-limiting toxicities. Early signs of induction of potentially beneficial inflammatory cytokines/chemokines, such as CXCL10. Phase 1b combination with checkpoint inhibitor to open in early 2024. Melbourne, Australia 6 November 2023 – ImmVirX Pty Limited, a life […]
Cancer-fighting biotech ImmVirX secures $15m from OneVentures
You can read the full story here.
ImmVirX raising $25m led by renowned healthcare VC OneVentures
– Up to A$25 million to be raised in Series B Financing, funding ImmVirX through to 2026 – Leading healthcare venture capital investor OneVentures subscribing for A$15 million – Up to $10 million to be raised from existing shareholders and placement of any shortfall – Dr Jeannie Joughin, a Principal at OneVentures, to join ImmVirX […]
OneVentures backs cancer biotech ImmVirX in $25 million Series B
You can read the full story here.
